Karoline V. Gleixner

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects

Karoline V. Gleixner, Matthias Mayerhofer, Karl J. Aichberger et al. · Blood · 2005 · 247 citations · Full text

Medicine, Cancer Biology, Pharmacology +12

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia

Wolfgang Warsch, Karoline Kollmann, Eva Eckelhart et al. · Blood · 2011 · 188 citations · Full text

Medicine, Cancer Biology, Molecular Biology +8

Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis

Georg Greiner, Bettina Sprinzl, Aleksandra Górska et al. · Blood · 2020 · 184 citations · Full text

Life Sciences, Genetics, Molecular Genetics +16

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)

Harald Herrmann, Katharina Blatt, Junwei Shi et al. · Oncotarget · 2012 · 154 citations · Full text

Medicine, Hematology, Oncology +16

Emicizumab for the treatment of acquired hemophilia A

Paul Knoebl, J. Thaler, Petra Jilma‐Stohlawetz et al. · Blood · 2020 · 147 citations · Full text

Medicine, Hematology, Pharmacotherapy +8